RxDoctor Payments Data

Yari Campbell, MD

Internal Medicine · Huntsville, ALNPI 1144398678

Payments from drug & device makers

$2,206in general payments, 2019–2025

Across 97 payments — averaging $22.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$891
  • AstraZeneca$262
  • Merck$180
  • Abbott$166
  • GSK$121
  • Pfizer$113
  • plus $472 from 12 others

What the payments were for

  • Food & beverage$2,206100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,206 in reported general payments places this provider in the 70th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$127,726
Medicare patients
232
Services billed
2,248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide173$164,875
Humira(Cf) PenAdalimumab16$113,375
MounjaroTirzepatide84$102,787
Trelegy ElliptaFluticasone/Umeclidin/Vilanter130$91,721
EliquisApixaban94$66,060
RybelsusSemaglutide33$63,878
RexultiBrexpiprazole30$43,542
JardianceEmpagliflozin43$38,456
Breztri AerosphereBudesonide/Glycopyr/Formoterol51$37,112
JanuviaSitagliptin Phosphate34$25,544
XareltoRivaroxaban38$24,859
FarxigaDapagliflozin Propanediol36$24,451
LinzessLinaclotide25$22,921
TrulicityDulaglutide22$17,304
UbrelvyUbrogepant14$14,488

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$891$242,498217 claims
Lilly USA, LLCMounjaro, Trulicity$110$120,092106 claims
GSKTrelegy Ellipta, Arexvy$121$94,504141 claims
PfizerEliquis, Nurtec Odt$113$77,896106 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort, Brilinta$262$75,132119 claims
Otsuka America Pharmaceutical, Inc.Rexulti$12$43,54230 claims
MerckJanuvia$180$25,54434 claims
Johnson & JohnsonXarelto$51$24,85938 claims
NovartisEntresto$41$9,27014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →